Peptide PilotPeptide Pilot

mg ↔ units

Retatrutide mg to units converter

Set your Retatrutide vial concentration once, then flip in either direction between milligrams and U-100 syringe units.

Download Peptide PilotiPhone · Free to download

mg

2.000

units

40.0

mL

0.400

Concentration: 5.00 mg/mL (assumes a U-100 insulin syringe).

Retatrutide is an experimental once-a-week injection people are tracking for weight loss and blood-sugar effects. It's the first triple agonist — it hits GLP-1, GIP, and glucagon receptors together, which appears to amplify both appetite suppression and energy expenditure. In a Phase 2 trial, adults with obesity lost about 24.2% of body weight at 48 weeks on the highest dose. It is still investigational and not approved. This page covers the reconstitution math and weekly logging cadence.

How the Retatrutide mg ↔ units converter works

This converter is a two-way bridge between dose mass (mg or mcg) and the unit count you actually draw on an insulin syringe. Once you set the Retatrutide concentration of your current vial, you can type any mg value and read the units back, or type any unit count and read the mg back. It is the same math as the dose calculator, but bidirectional, which matters when you are checking a dose someone else recorded in units against a protocol written in mg.

The formula in both directions: mg = mL × concentration mg/mL, and units = mL × 100 on a U-100 syringe. With a 5 mg/mL Retatrutide solution, 2 mg comes out to 40 units, and 40 units comes out to 2 mg. The converter handles the unit flip automatically so you never multiply or divide in your head while holding a syringe.

Concentration is the input that changes the answer most. A 10 mg vial diluted with 1 mL is twice as concentrated as the same vial diluted with 2 mL, which means the same dose draws half as many units. That is the single biggest source of converter confusion: a remembered unit count from an old vial does not transfer to a new vial reconstituted with different water volume.

Use the converter whenever a protocol or research note is written in one unit and your syringe is labeled in the other. It is also useful for sanity-checking that a planned titration step lands at a unit count you can read accurately on the syringe — under five units gets hard to read, over fifty starts crowding into the back third of a 1 mL syringe.

Why this matters for Retatrutide

Retatrutide is an investigational synthetic peptide that activates three incretin and metabolic receptors at once — GIP, GLP-1, and glucagon. It is the next-generation extension of the dual-agonist concept that tirzepatide pioneered, and it is currently the subject of pharmaceutical clinical trials.

Because retatrutide has not been approved as a finished pharmaceutical at the time of writing, it is encountered almost exclusively as a lyophilized research-grade peptide in milligram-rated vials. Common vial sizes in the research market range from 5 mg to 20 mg or larger.

Like the other long-acting incretin peptides on this site, retatrutide is typically logged on a once-weekly cadence. The weekly rhythm shapes how vials are reconstituted, how doses escalate over time, and how vial duration is estimated for refill planning.

Retatrutide mechanism in plain English

Retatrutide binds to the GIP, GLP-1, and glucagon receptors. The first two are familiar from semaglutide and tirzepatide; the addition of glucagon-receptor activation is what differentiates retatrutide from those earlier peptides and is the focus of much of its ongoing clinical research.

Triple-receptor activation produces metabolic effects that are still being characterized in published trials. Anyone tracking retatrutide in a personal log should pair the dose history with weekly metrics like weight, hunger ratings, and side-effect notes — that pairing is what turns a list of injections into a usable trend.

The compound's pharmacology is defined by its activity as a single-molecule agonist for the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. While co-activation of GLP-1 and GIP receptors is also the mechanism of tirzepatide, the addition of the glucagon receptor agonist component is what makes retatrutide a distinct investigational agent. In metabolic physiology, glucagon signaling is traditionally associated with stimulating the liver to produce glucose. However, researchers are studying how its concurrent activation with potent incretin mimetics like GLP-1 and GIP might influence energy expenditure, lipid metabolism, and appetite signaling in ways that are distinct from single- or dual-agonist peptides.

Tracking Retatrutide unit counts

Because retatrutide is investigational, careful logging is even more valuable than usual: pairing dose, escalation date, weight, hunger ratings, and side effects produces a record that is genuinely useful both to the individual and to a healthcare professional reviewing the history later.

Given the aggressive dose-escalation schedules observed in clinical trial data, detailed titration-schedule logging is an even more important component of personal data collection than for other incretin mimetics. A personal log should not only record the dose amount but also meticulously document the date of each upward titration. Tracking how the subject responds to each new dose level—for example, the transition from 4 mg to 8 mg—provides a granular dataset. This documentation allows for a clear audit of the titration velocity and helps contextualize any observations logged during the period, associating them with a specific, time-stamped dose level within the rapid escalation structure being studied.

Common Retatrutide conversion mistakes

  • Reusing a unit count from a previous vial without re-checking the new vial's diluent volume.
  • Confusing retatrutide doses with semaglutide or tirzepatide doses — the milligram ranges differ and the math does not transfer.
  • Skipping the escalation date in the log, then losing the timeline of when each step actually occurred.
  • Letting reconstituted retatrutide warm to room temperature for extended periods on travel days.
  • Not writing the reconstitution date on the vial itself — the in-use window is long enough that an unmarked vial becomes ambiguous.
  • Assuming retatrutide has established prescribing information and failing to recognize its investigational-only status.
  • Neglecting to calculate injection volume for high-end doses, leading to logistical issues with standard 1 mL syringes.
  • Incorrectly logging it as a dual-agonist peptide, confusing its unique triple-receptor mechanism with that of tirzepatide.

Frequently asked questions about Retatrutide mg ↔ units

How is retatrutide reconstituted?
By drawing a measured volume of bacteriostatic water into a syringe and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves into a clear solution.
How many units of retatrutide are in 2 mg?
It depends on the concentration of your vial. On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 2 mg is exactly 40 units on a U-100 syringe.
Is retatrutide approved as a pharmaceutical?
Not at the time of writing. Retatrutide is investigational and is currently being studied in pharmaceutical clinical trials. Anything beyond that — including dosing decisions — is a conversation for a licensed healthcare professional, not for a calculator page.
How long does a 10 mg vial of retatrutide last?
At a 2 mg weekly dose, a 10 mg vial provides 5 doses, or 5 weeks of supply. The vial duration calculator runs the math for any combination of vial size, dose, and frequency.
Why does retatrutide get tracked the same way as semaglutide?
Because the underlying logging shape is the same: weekly long-acting peptide, lyophilized vial, gradual dose escalation, paired weekly metrics. The math, the vial workflow, and the refill cadence are all structurally identical even though the molecule is different.
Does retatrutide need to be refrigerated?
Lyophilized powder is typically stored refrigerated, and the reconstituted vial is kept refrigerated and used within several weeks. Repeated temperature cycling reduces stability, so storing the vial in the door of the refrigerator is best avoided.
How does retatrutide's mechanism differ from semaglutide's mechanism?
The primary difference is the number of hormone receptors they target. Semaglutide is a single agonist, designed to activate only the glucagon-like peptide-1 (GLP-1) receptor. Retatrutide is a triple agonist, engineered to concurrently activate the GLP-1 receptor, the GIP receptor, and the glucagon receptor.
How does retatrutide's mechanism differ from tirzepatide's mechanism?
The key distinction is the addition of a third target receptor. Tirzepatide is a dual agonist that activates both the GLP-1 and GIP receptors. Retatrutide expands on this by also activating the glucagon receptor, making it a triple-agonist compound. The glucagon receptor activation is the novel component not present in tirzepatide.
Why are the doses logged for retatrutide different from other peptides?
Retatrutide is an investigational compound without any approved dosing guidelines. The doses that are tracked and logged are based on data from published clinical trials. These studies have explored specific, escalating dose schedules that reach higher magnitudes, such as 8 mg or 12 mg per week, than the typical terminal doses for commercially available GLP-1 agonists.

Related on Peptide Pilot

Save your Retatrutide vial in the app

Download on the App Store
Get the App